J Korean Rheum Assoc.  2007 Dec;14(4):331-339.

Clinical Features and Course of Systemic Onset Juvenile Rheumatoid Arthritis

• Kim JE
• Bang SY
• Ahn SB
• Rim KN
• Kim HS
• Uhm WS
• Kim TH
• Jun JB
• Bae SC
• Yoo DH

Abstract

OBJECTIVE
Juvenile rheumatoid arthritis (JRA) is classified as polyarticular, oligoarticular, and systemic onset type by clinical symptoms presented during first six months. This study was performed to investigate the clinical features and course of systemic onset JRA.
METHODS
We performed a retrospective study for patients who were diagnosed as JRA between March 2000 and March 2006 according to the JRA criteria of the International League of Association for Rheumatology (ILAR).
RESULTS
Of the 216 JRA patients, 33 patients (11 male/ 22 female) were systemic onset type. Because of insufficient data, 6 patients were excluded. Chief complaints at the time of diagnosis were fever (81.5%) and arthralgia (77.7%). During the disease course, all patients manifested fever and arthritis, rash (59.2%) and splenomegaly (22.2%) also occurred. Most patients had symmetric (81.5%) arthritis, and involved more than five joints (59.3%) including knee and wrist. Anemia, leukocytosis, and thrombocytosis were common laboratory abnormalities. Almost all patients had elevated level of C-reactive protein and erythrocyte sediment rate. Some patients had positive results about immunologic marker such as rheumatoid factor (3.8%), antinuclear antibody (57.7%), and antiperinuclear factor (9.5%). Therapeutic regimens included glucocorticoids (88.9%), nonsteroidal anti-inflammatory drugs (81.5%), methotrexate (81.5%), and hydroxychloroquine (55.6%). Biologic agents were applied in 5 patients, and 3 showed improvement of disease activity. Combination therapy was introduced in 18.5% of patients, and 63% of patients still required medications.
CONCLUSION
In Korea, systemic onset JRA patients had variable clinical manifestations and chronic course of disease, which often extended into adulthood.

Keyword

Juvenile rheumatoid arthritis; Systemic onset

MeSH Terms

Anemia
Antibodies, Antinuclear
Arthralgia
Arthritis
Arthritis, Juvenile*
Biological Factors
Biomarkers
C-Reactive Protein
Diagnosis
Erythrocytes
Exanthema
Fever
Glucocorticoids
Humans
Hydroxychloroquine
Joints
Knee
Korea
Leukocytosis
Methotrexate
Retrospective Studies
Rheumatoid Factor
Rheumatology
Splenomegaly
Thrombocytosis
Wrist
Antibodies, Antinuclear
Biological Factors
C-Reactive Protein
Glucocorticoids
Hydroxychloroquine
Methotrexate
Rheumatoid Factor

Figure

• 

  Fig. 1. Age distribution of systemic onset JRA at onset.

Reference

1). Mason TG., Reed AM. Update in juvenile rheumatoid arthritis. Arthritis Rheum. 2005. 53:796–9.

2). Brewer EJ Jr., Bass J., Baum J., Cassidy JT., Fink C., Jacobs J, et al. Current proposed revision of JRA Criteria. JRA Criteria Subcommittee of the Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Section of The Arthritis Foundation. Arthritis Rheum. 1977. 20:195–9.

3). Cassidy JT., Levinson JE., Bass JC., Baum J., Brewer EJ Jr., Fink CW, et al. A study of classification criteria for a diagnosis of juvenile rheumatoid arthritis. Arthritis Rheum. 1986. 29:274–81.

4). Harris ED., Budd RC., Firestein GS., Genovese MC., Sergent JS., Ruddy S, et al. Kelley's textbook of rheumatology. 7th ed.p. 1579. Philadelphia, W.B. Saunders;2004.

5). Woo P., Wedderburn LR. Juvenile chronic arthritis. Lancet. 1998. 351:969–73.

6). Yilmaz M., Kendirli SG., Altintas D., Bingol G., Antmen B. Cytokine levels in serum of patients with juvenile rheumatoid arthritis. Clin Rheumatol. 2001. 20:30–5.

7). Pascual V., Allantaz F., Arce E., Punaro M., Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med. 2005. 201:1479–86.

8). Schneider R., Passo MH. Juvenile rheumatoid arthritis. Rheum Dis Clin North Am. 2002. 28:503–30.

9). Manners PJ., Bower C. Worldwide prevalence of juvenile arthritis why does it vary so much? J Rheumatol. 2002. 29:1520–30.

10). Danner S., Sordet C., Terzic J., Donato L., Velten M., Fischbach M, et al. Epidemiology of juvenile idiopathic arthritis in Alsace, France. J Rheumatol. 2006. 33:1377–81.

11). Hanova P., Pavelka K., Dostal C., Holcatova I., Pikhart H. Epidemiology of rheumatoid arthritis, juvenile idiopathic arthritis and gout in two regions of the Czech Republic in a descriptive population-based survey in 2002-2003. Clin Exp Rheumatol. 2006. 24:499–507.

12). 김중곤: 정주영: 윤보영: 한윤수. 연소성류마티스관절염에대한임상적고찰(I. 전신형). 대한류마티스학회지. 1994. 1:175–82.

13). Baksiene D., Kasparaviciene J., Zebiene M., Puteliene B. Juvenile idiopathic systemic arthritis. Medicina (Kaunas). 2003. 39:751–5.

14). Spiegel LR., Schneider R., Lang BA., Birdi N., Silverman ED., Laxer RM, et al. Early predictors of poor functional outcome in systemic-onset juvenile rheumatoid arthritis: a multicenter cohort study. Arthritis Rheum. 2000. 43:2402–9.

15). Ramanan AV., Schneider R., Batthish M., Achonu C., Ota S., McLimont M, et al. Developing a disease activity tool for systemic-onset juvenile idiopathic arthritis by international consensus using the Delphi approach. Rheumatology (Oxford). 2005. 44:1574–8.

16). Cunha BA. Fever of unknown origin caused by adult juvenile rheumatoid arthritis: the diagnostic significance of double quotidian fevers and elevated serum ferritin levels. Heart Lung. 2004. 33:417–21.

17). Woo P., Wilkinson N., Prieur AM., Southwood T., Leone V., Livermore P, et al. Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res Ther. 2005. 7:R1281–8.

18). Hur M., Kim YC., Lee KM., Kim KN. Macrophage activation syndrome in a child with systemic juvenile rheumatoid arthritis. J Korean Med Sci. 2005. 20:695–8.

19). Kim TY., Chang CS., Kim SY. A new substrate (ΓΓ-1) for the antinuclear antibody (ANA) test. Arthritis Rheum. 1994. 37(Suppl):s317.

20). Kim TY., Chang CS., Kim SY. New autoantibodies (anti-MTOC) detected by macrophage cell line (IT-1) in rheumatoid arthritis. Arthritis Rheum. 1995. 38(Suppl):s255.

21). el-Gamal Y., Hossny E., Mabrouk R., el-Gamasey T. Antiperinuclear factor in the diagnosis of juvenile rheumatoid arthritis. Pediatr Allergy Immunol. 1995. 6:165–9.

22). 김신규: 오지하: 서일혜: 김덕언: 장성렬: 유대현등. 류마티스관절염의새로운표지자항체Antiperinuclear factor (APF)에관한연구. 대한면역학회. 1994. 16:109–13.

23). Nesher G., Moore TL., Grisanti MW., el-Najdawi E., ᄋsborn TG. Antiperinuclear factor in juvenile rheumatoid arthritis. Ann Rheum Dis. 1992. 51:350–2.

24). Brooks CD. Sulfasalazine for the management of juvenile rheumatoid arthritis. J Rheumatol. 2001. 28:845–53.

25). Lurati A., Pontikaki I., Teruzzi B., Desiati F., Gerloni V., Gattinara M, et al. A comparison of response criteria to evaluate therapeutic response in patients with juvenile idiopathic arthritis treated with methotrexate and/or anti-tumor necrosis factor alpha agents. Arthritis Rheum. 2006. 54:1602–7.

26). Iesaka K., Kubiak EN., Bong MR., Su ET., Di Cesare PE. Orthopedic surgical management of hip and knee involvement in patients with juvenile rheumatoid arthritis. Am J ᄋrthop. 2006. 35:67–73.

27). ᄋen K., Malleson PN., Cabral DA., Rosenberg AM., Petty RE., Cheang M. Disease course and outcome of juvenile rheumatoid arthritis in a multicenter cohort. J Rheumatol. 2002. 29:1989–99.

28). Wallace CA., Levinson JE. Juvenile rheumatoid arthritis: outcome and treatment for the 1990s. Rheum Dis Clin North Am. 1991. 17:891–905.

29). Minden K., Kiessling U., Listing J., Niewerth M., Doring E., Meincke J, et al. Prognosis of patients with juvenile chronic arthritis and juvenile spondyloarthropathy. J Rheumatol. 2000. 27:2256–63.

30). Lomater C., Gerloni V., Gattinara M., Mazzotti J., Cimaz R., Fantini F. Systemic onset juvenile idiopathic arthritis: a retrospective study of 80 consecutive patients followed for 10 years. J Rheumatol. 2000. 27:491–6.

31). Zak M., Pedersen FK. Juvenile chronic arthritis into adulthood: a long-term follow-up study. Rheumatology (Oxford). 2000. 39:198–204.